Valeant Pharmaceuticals Intl (NYSE:VRX) Given a $25.00 Price Target at Cantor Fitzgerald

Cantor Fitzgerald set a $25.00 price target on Valeant Pharmaceuticals Intl (NYSE:VRX) (TSE:VRX) in a research note released on Friday, January 19th. The firm currently has a buy rating on the specialty pharmaceutical company’s stock.

“There has been some concern that VRX’s Xifaxan could face competition from Cosmo Pharmaceuticals (Not Covered) as early as 2019. We reiterate our Overweight rating and price target of $25; we don’t see fundamental reasons for the stock’s weakness this morning.”,” Cantor Fitzgerald’s analyst commented.

Several other analysts also recently issued reports on VRX. ValuEngine upgraded Valeant Pharmaceuticals Intl from a hold rating to a buy rating in a report on Monday, October 2nd. TD Securities raised shares of Valeant Pharmaceuticals Intl from a hold rating to a buy rating and set a $20.00 price objective for the company in a research report on Friday, November 3rd. Vetr cut shares of Valeant Pharmaceuticals Intl from a strong-buy rating to a buy rating and set a $19.18 price objective for the company. in a research report on Monday, December 4th. HC Wainwright upped their price objective on shares of Valeant Pharmaceuticals Intl from $17.00 to $24.00 and gave the company a buy rating in a research report on Tuesday, January 16th. Finally, TheStreet raised shares of Valeant Pharmaceuticals Intl from a d rating to a c- rating in a research report on Tuesday, November 7th. Seven investment analysts have rated the stock with a sell rating, nine have issued a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of Hold and a consensus price target of $18.59.

Shares of Valeant Pharmaceuticals Intl (NYSE:VRX) traded up $0.42 on Friday, reaching $18.37. The company’s stock had a trading volume of 6,706,100 shares, compared to its average volume of 13,820,000. The firm has a market cap of $6,410.00, a P/E ratio of 4.71, a PEG ratio of 0.56 and a beta of -0.42. The company has a debt-to-equity ratio of 4.84, a current ratio of 1.26 and a quick ratio of 1.03. Valeant Pharmaceuticals Intl has a 52 week low of $8.31 and a 52 week high of $24.43.

In other news, Director John Paulson acquired 344,216 shares of the firm’s stock in a transaction that occurred on Thursday, November 16th. The stock was purchased at an average price of $14.40 per share, with a total value of $4,956,710.40. Following the purchase, the director now owns 94,559 shares of the company’s stock, valued at approximately $1,361,649.60. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 5.87% of the company’s stock.

Several large investors have recently modified their holdings of VRX. Eaton Vance Management boosted its stake in shares of Valeant Pharmaceuticals Intl by 1.2% during the 2nd quarter. Eaton Vance Management now owns 43,469 shares of the specialty pharmaceutical company’s stock valued at $752,000 after buying an additional 500 shares during the period. Stephens Inc. AR bought a new position in shares of Valeant Pharmaceuticals Intl during the 2nd quarter valued at $299,000. TIAA CREF Investment Management LLC raised its holdings in shares of Valeant Pharmaceuticals Intl by 36.8% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 609,290 shares of the specialty pharmaceutical company’s stock valued at $10,575,000 after purchasing an additional 164,053 shares in the last quarter. Nationwide Fund Advisors raised its holdings in shares of Valeant Pharmaceuticals Intl by 1.7% during the 2nd quarter. Nationwide Fund Advisors now owns 52,400 shares of the specialty pharmaceutical company’s stock valued at $907,000 after purchasing an additional 900 shares in the last quarter. Finally, GSA Capital Partners LLP raised its holdings in shares of Valeant Pharmaceuticals Intl by 10.5% during the 2nd quarter. GSA Capital Partners LLP now owns 21,651 shares of the specialty pharmaceutical company’s stock valued at $375,000 after purchasing an additional 2,051 shares in the last quarter. 48.49% of the stock is owned by institutional investors.

WARNING: This piece was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/02/14/valeant-pharmaceuticals-intl-vrx-given-a-25-00-price-target-by-cantor-fitzgerald-analysts.html.

About Valeant Pharmaceuticals Intl

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals Intl (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply